Patient P-01492

Synthetic patientNBL-101 · Day 112 · 35–44 · F · baseline S15Open companion preview

Therapy response

Stable

Tolerance

Unstable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

86%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S15
Day 52 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 54 GI-04 recommended — GI Support Protocol GI-04
Day 55 Patient declined — Not now
Day 70 ME-01 recommended — Monitoring Escalation ME-01
Day 71 Patient accepted — Started ME-01 in the companion
Day 74 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 52.

Primary contributors, last 14 days

GI instability-15
Inflammatory activity-14
Nutritional resilience+4
Treatment adherence+2

What helped?

GI Support Protocol GI-04Day 54
Declined by patient
Monitoring Escalation ME-01Day 70
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 63
- WearableHRV 22 ms, trending down
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 65 and rising
Butyrate / short-chain fatty acid production ↓45
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓45
- WearableResting HR 78 bpm
- Wearable300 steps/day
Drug metabolism and exposure ↑20
- BloodToxicity index 60

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Rapid metabolizer
Expected exposure

Microbiome

Shannon diversity 2.1 · butyrate capacity 47/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 19 ms
Sleep: 6.6 h
Steps: 422
Resting HR: 79 bpm

Daily log: GI score 65, nutritional resilience 27, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01454	50%	S14	GI-04	no change	49
P-01760	50%	S14	—	—	42
P-01776	49%	S16	NP-02	no change	47
P-01826	49%	S10	—	—	42
P-01407	47%	S14	NP-02	no change	44
P-01582	47%	S14	GI-04	no change	45
P-01605	47%	S14	ME-01	improved	41
P-01751	47%	S14	ME-01	improved	48
P-01762	47%	S14	NP-02	no change	40
P-01772	45%	S20	NP-02	no change	50
P-01799	45%	S19	NP-02	no change	51
P-01440	44%	S12	GI-04	no change	51